A Phase 3, Randomized, Double-blind, Multicenter Study Comparing TSR-042 plus Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin plus Placebo in Patients with Recurrent or Advanced Endometrial Cancer Who Had Received no Previous Systemic Anticancer therapy for Advanced or Metastatic Disease

Sponsor: GSK/Tesaro

Participating sites:

  • UZ Leuven, Leuven
  • CHU de Liège, site Sart Tilman, Liège
  • OLV Aalst, Aalst